Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one

Human Gene Therapy

Volumn 7, Issue 17, 1996, Pages 2059-2068

  Heuer, Josef G ^a   Tucker McClung, Cheryl ^a   Gonin, Rene ^a   Hock, Randy A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE TRANSFER; IMMUNOGENICITY; MOUSE; NEUROBLASTOMA; NONHUMAN; RETROVIRUS; SPLEEN CELL; T LYMPHOCYTE; VACCINATION;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0029801726     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.17-2059     Document Type: Article

References (34)

1. ARMITAGE, P., and BERRY, G. (1987). Statistical Methods in Medical Research. (Blackwell Scientific Publications, Oxford, UK) pp. 429-433.
2. BASKAR, S., NABAVI, N., GLIMCHER, L.H., and OSTRAND-ROSENBERG, S. (1993). Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immunother. 14, 209-215.
3. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629.
4. BOON, T. (1992). Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58, 177-210.
5. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD, B.R., MURPHY M., WOLF, S.J., and GATELY, M.K. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230.
6. CHEN, L., ASHE, S., BRADY, W.A., HELLSTRÖM, I., HELLTRÖM, K.E., LEDBETTER, J.A., MCGOWAN, P., and LENSLEY, P.S. (1992). Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
7. CHEN, L., MCGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTRÖM, I., and HELLSTRÖM, K.E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
8. CULVER, K.W., and BLAESE, R.M. (1994). Gene therapy for cancer. Trends. Genet. 10, 174-178.
9. DRANOFF, G., and MULLIGAN, R.C. (1995). Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454.
10. FREEMAN, G.J., GRAY, G.S., GIMMI, C.D., LOMBARD, D.B., ZHOU, L.J., WHITE, M., FINGEROTH, J.D., GRIBBEN, J.B., and NADLER, L.M. (1991). Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631.
11. GIMMI, C.D., FREEMAN, G.J., GRIEBEN, J.G., SUGITA, K., FREEDMAN, A.S., MORIMOTO, C., and NADLER, L.M. (1991). B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete IL-2. Proc. Natl. Acad. Sci. USA 88, 6575-6579.
12. GRAY, G.S., FREEMAN, G.J., GIMMI, C.D., LOMBARD, D.B., ZHOU, L.J., WHITE, M., FINGEROTH, J.D., GRIEBEN, J.B., and NADLER, L.M. (1991). Structure, expression, and T cell stimulatory activity of the murine homolog of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631.
13. GUINAN, E.C., GRIBBEN, J.G., BOUSSIOTIS, V.A., FREEMAN, G.J., and NADLER, L.M. (1994). Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-3282.
14. HOCK, R.A., REYNOLDS, B.D., TUCKER-MCCLUNG, C.L., and KWOK, W.W. (1995). Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J. Immunother. 17, 12-18.
15. HOCK, R.A., REYNOLDS, B.D., TUCKER-MCCLUNG, C.L., and HEUER, J.G. (1996). Murine neuroblastoma vaccines produced by retroviral transfer of MHC class II genes. Cancer Gene Ther. 3, 314-320.
16. HUI, K., GROSVELD, F., and FESTENSTEIN, H. (1984). Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311, 750-752.
17. JAMES, R.F.L., EDWARDS, S., HUI, K.M., BASSETT, P.D., and GROSVELD, F. (1991). The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology 72, 213-218.
18. KAPLAN, E.L., and MEIER, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Statist. Assn. 53, 457-481.
19. KATSANIS, E., XU, Z., BAUSERO, M.A., DANCISAK, B.B., GORDEN, K.B., DAVIS, G., GRAY, G.S., ORCHARD, P.J., and BLAZAR, B.R. (1995). B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther. 2, 39-46.
20. KUCHROO, V.K., DAS, M.P., BROWN, J.A., RANGER, A.M., ZAMVIL, S.S., SOBEL, R.A., WEINER, H.L., NABAVI, N., and GLIMCHER, L.H. (1995). B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, 707-718.
21. LIANG, P., and PARDEE, A.B. (1995). Polymerase chain reaction. In Current Protocols in Molecular Biology. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl, L.M. Albright, D.M. Coen, and A. Varki, eds. (John Wiley, New York) pp. 15.0.1-15.8.8.
22. LINSLEY, P.S., BRADY, W., GROSMARIE, L., ARUFFO, A., DAMLE, N., and LEDBETTER, J.A. (1991). Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730.
23. MELIEF, C.J.M. (1992). Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143-175.
24. MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895-2902.
25. OSTRAND-ROSENBERG, S. (1994). Tumor immunotherapy: The tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6, 722-727.
26. OSTRAND-ROSENBERG, S., THAKUR, A., and CLEMENTS, V. (1990). Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144, 4068-4071.
27. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
28. SANGER, F., NICKLEN, S., and COULSON, A.R. (1977). DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463-5467.
29. TANAKA, K., ISSELBACHER, K., KHOURY, G., and JAY, G. (1985). Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228, 26-30.
30. TJOA, B.A., and KRANZ, D.M. (1994). Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 54, 204-208.
31. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
32. VAN DER BRUGGEN, P. (1994). The long-standing quest for tumor rejection antigens. Clin. Immunol. Immunopathol. 71, 248-252.
33. WALLICH, R., BULBUC, N., HÄMMERLING, G.J., KATZAV, S., SEGAL, S., and FELDMAN, M. (1985). Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315, 301-305.
34. YANG, J.C., and ROSENBERG, S.A. (1991). Adoptive cellular therapy: Preclinical studies. In Biologic Therapy of Cancer. V.T. DeVita, S. Hellman, and S.A. Rosenberg, eds. (JB Lippincott, Philadelphia) pp. 197-213.